P-Values

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance. 

Featured

Blog Post

All things alimatravir (AMI)

AVAC and partners have been engaging with Merck/MSD since the very start of the alimatravir product development program and helped conceptualize the EXPrESSIVE efficacy trial design. Building on this foundation of community-centricity, advocates can now push for AMI to be rolled out with speed, scale and equity. Since 2012, each successive PrEP introduction has gone faster than the previous one, yet the time to market and to public health impact for PrEP remains too slow. Read on for AVAC’s insights on AMI, from accelerated licensing and affordability to community priorities and meaningful engagement.

Read more

Blog Post

Global Health Watch: NIH-DoD Deal & NIAID Restructuring, Ebola Vaccine Progress, Gavi Funding Resumes, New US Foreign Aid Leadership

The US National Institutes of Health (NIH) signs a 10-year agreement that could move significant NIAID research funding to the Department of Defense, as NIAID separately proposes a major restructuring of its clinical research infrastructure. CEPI advances efforts toward a Bundibugyo Ebola vaccine amid funding gaps, while US funding for Gavi resumes and medical groups step in on vaccine guidance. And new leadership at the Department of State brings further change to the US foreign assistance system.

Read more

Blog Post

The Impact Report: Two Decades of Good Participatory Practice in HIV Research 

Scientific breakthroughs in HIV prevention depend on community engagement that drives successful research, development, acceptance and uptake of new products. In 2007, emerging from controversies that halted the first ever PrEP efficacy trials, AVAC and UNAIDS led a global partnership to develop the Good Participatory Practice (GPP) Guidelines, offering systematic guidance on how to engage stakeholders throughout HIV prevention trials. Almost twenty years later, GPP is the gold standard for engagement in HIV prevention research and beyond. This edition of the Impact Report celebrates two decades of GPP, and shares how AVAC and our research and civil society partners have effectively integrated GPP into HIV prevention.

Read more

Filter by

Reset filters

P-Values

showing 1-10 of 1266

All things alimatravir (AMI)

AVAC and partners have been engaging with Merck/MSD since the very start of the alimatravir product development program and helped conceptualize the EXPrESSIVE efficacy trial design. Building on this foundation of community-centricity, advocates can now push for AMI to be rolled out with speed, scale and equity. Since 2012, each successive PrEP introduction has gone faster than the previous one, yet the time to market and to public health impact for PrEP remains too slow. Read on for AVAC’s insights on AMI, from accelerated licensing and affordability to community priorities and meaningful engagement.

Prevention Option:

Topic:

September 2026

Global Health Watch: NIH-DoD Deal & NIAID Restructuring, Ebola Vaccine Progress, Gavi Funding Resumes, New US Foreign Aid Leadership

The US National Institutes of Health (NIH) signs a 10-year agreement that could move significant NIAID research funding to the Department of Defense, as NIAID separately proposes a major restructuring of its clinical research infrastructure. CEPI advances efforts toward a Bundibugyo Ebola vaccine amid funding gaps, while US funding for Gavi resumes and medical groups step in on vaccine guidance. And new leadership at the Department of State brings further change to the US foreign assistance system.

Prevention Option:

Topic:

September 2026

The Impact Report: Two Decades of Good Participatory Practice in HIV Research 

Scientific breakthroughs in HIV prevention depend on community engagement that drives successful research, development, acceptance and uptake of new products. In 2007, emerging from controversies that halted the first ever PrEP efficacy trials, AVAC and UNAIDS led a global partnership to develop the Good Participatory Practice (GPP) Guidelines, offering systematic guidance on how to engage stakeholders throughout HIV prevention trials. Almost twenty years later, GPP is the gold standard for engagement in HIV prevention research and beyond. This edition of the Impact Report celebrates two decades of GPP, and shares how AVAC and our research and civil society partners have effectively integrated GPP into HIV prevention.

September 2026

Using a Transformative Human-Centered Design Approach to Co-Create Communication Materials for the Alimatravir Efficacy Trial, EXPrESSIVE-11

Merck’s EXPrESSIVE program is investigating the efficacy of alimatravir (AMI) for monthly oral PrEP. With support from the Gates Foundation, AVAC works to ensure there is strong, consistent engagement with community representatives to influence the design and implementation of the trials, with an eye toward future rollout and access planning. Leveraging expertise in community engagement and human-centered design, AVAC worked in partnership with community-based organizations on three continents to co-create communications materials for the EXPrESSIVE-11 trial – conducted among men who have sex with men (MSM), transgender, and non-binary people – that are driven by community perspectives and lived realities.

September 2026

The Clinical Trial Design Academy: Equipping Advocates to Shape HIV Prevention Research Decisions and Move the Research Agenda Forward

As clinical trial research becomes increasingly complex, and as innovative HIV prevention products advance through the pipeline, advocates with dual skillsets – deep contextual knowledge of their community’s needs and scientific and technical knowledge – are increasingly sought after to provide critical community input in research that aligns with GPP and holds researchers accountable. AVAC’s Clinical Trial Design Academy equips advocates with the scientific knowledge and skillset to influence research – from priority setting to trial design and conduct, to results dissemination.

September 2026

Embedding Good Participatory Practice in PURPOSE 1

AVAC collaborates with partners around the world to embed GPP principles in advocacy strategies and partnerships and cultivates a diverse network of advocates, civil society organizations, journalists, researchers, and implementers who champion GPP and are equipped to engage with and influence HIV clinical trial research. Gilead’s PURPOSE program investigates the efficacy of long-acting injectable lenacapavir (LEN) for PrEP among diverse populations. For PURPOSE 1 and PURPOSE 2, embedding GPP principles promoted accountability, transparency, and meaningful community engagement throughout trial design and conduct.

Prevention Option:

Topic:

September 2026

Global Health Watch: Steinem’s Legacy, US Global Health Aid Cuts; OMB Grant Rule Delayed; Future of Global Health Reform

We’ve lost another champion for global health and reproductive rights this week: Gloria Steinem, the pioneering feminist and activist who spent decades fighting for gender equality, reproductive choice and the power of people to shape the decisions that affect their lives. This is a reminder to continue questioning who has a voice, who gets to decide, and why bodily autonomy is a fundamental right. This week’s issue addresses those questions: a new analysis finds US bilateral health agreements could dramatically reduce global health funding by more than half; Congress has temporarily blocked the White House OMB’s effort to expand political control over federal grants; and, as global health architecture reform moves forward, civil society is demanding a role in shaping what comes next.

Prevention Option:

Topic:

September 2026

Global Health Watch: Legacies of Parton & Goosby, expiring global health funds, Jeremy Lewin’s move, Ebola funding & vaccine R&D

This week, the global health community lost a powerful, if unlikely, champion in Dolly Parton. Longtime leader Eric Goosby, who served as the US Global AIDS Coordinator and led the President’s Emergency Plan for AIDS Relief (PEPFAR) from 2009 to 2013 under President Barack Obama, officially retired this week. Also this week, members of the US Congress demanded that the Administration release billions in congressionally-appropriated global health funding; another leadership change is underway at the Department of State; and in the DRC, the Ebola response is making progress even as inadequate funding threatens efforts.

Prevention Option:

Topic:

August 2026

Global Health Watch: NIH reopens South Africa Research Funding; DRC Ebola Strains Outbreak Response; WHO + FDA Leadership Shifts

The US National Institutes of Health (NIH) lifted research funding restrictions on South Africa; the DRC’s Ebola outbreak grows, exposing the consequences of weakened outbreak-response systems; and leadership changes at the World Health Organization (WHO) and the US Food and Drug Administration (FDA) raise questions about the future of global health decision-making.

Prevention Option:

Topic:

August 2026

The Latest Resources from AVAC: Advancing Science, Expanding Access

Scientific breakthroughs accelerate HIV prevention—but only when they are matched with bold advocacy, sustained investment and equitable access. This month’s roundup highlights key prevention news, developments and takeaways from AVAC and explores what’s needed and what’s next to ensure the latest innovations move beyond headlines and into the hands of the communities that need them most.

Prevention Option:

Topic:

August 2026

showing 1-10 of 1266

Explore More News and Communications

P-Values Blog

Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.

Advocates Network

AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.

Weekly News Digest

A comprehensive round-up of HIV prevention media coverage and scientific publications.

PxPulse

Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.

PxWire

PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.

Pandemic Watch

Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.

Press Releases

A collection of official statements from AVAC.

AVAC in the News

Media clippings featuring AVAC, its staff and close partners in the news media.